Our Team

At T-Cypher Bio, we share a commitment to making a difference for patients by making innovative drugs with curative potential. Working with passion towards our goals unites us.

Our team spans geographies and comprises young scientists with incredible talent to senior drug developers with a track record of developing successful biotech companies.

Sarah Leonard

Interim CEO

Rebecca Ashfield

Chief Development Officer

Scott Peterson

Chief Business Officer

Mark Lees

Vice President Corporate Development

Nathaniel Davies

Vice President Computational Biology

Thomas Lars Andresen

Founding CEO / Advisor

Graham Ogg

Chair of SAB

Owen Hughes

Independent Chair

Thomas Lars Andresen

Founding CEO / Non-Executive Director

Sohaib Mir

Life Arc

Claire Brown

Oxford Science Enterprises

Phil Ferneau

Borealis

Careers

Join T-Cypher Bio if you have a strong desire to make a difference, if you like standing out as an individual but also as part of a team, and if you have the drive to make the most of every day.

Please click below to apply to one of our open positions or, if you have in-depth experience in Antibody development, T cell biology, immunology, bioinformatics, or AI and/or TCR discovery and development, send your CV and cover letter to [email protected]

See current openings

Our investors

T-Cypher has the backing of leading specialist long-term investors who share our passion and commitment, enabling us to continue our journey to deliver lifesaving therapeutics.